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Medical Products of Human Origin (MPHO) encompass all substances that are derived 
wholly or in part from the human body and intended for clinical application. The presence of 
components of the human body in the therapeutic armamentarium may be thought of as a 
form of "survivor cannibalism" (Youngner 2003, 720): appropriation by necessity of 
biological materials without which we could not provide a range of medical products that 
offer the most effective treatment or indeed the sole remedy for many conditions impairing 
human health and wellbeing. MPHO consist in or are derived from anatomical components 
retrieved from the bodies of living persons or from those of the dead, as well as their 
secretions and excretions. Examples include: organs for transplantation; blood and plasma 
products; tissue and cell products such as skin grafts for burns and bone matrix materials used 
in dentistry; ova and sperm used in assisted reproductive treatments (ART); and breast milk 
used to treat premature infants.  
   Dependence on human beings to provide the components required for MPHO distinguishes 
them from all other medical products. This dependence carries a range of unique 
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responsibilities to ensure ethical and safe procurement, distribution and use of MPHO: 
prerequisites for societal acceptance of the public as source of the necessary human materials. 
For this reason, the World Health Organization (WHO) has established an organization wide 
initiative for MPHO to develop a framework for global governance addressing the issues of 
self-sufficiency in MPHO and the non-commercial nature of the human body and its parts as 
such. In this chapter, we explain the importance of this initiative and introduce its core 
strategic elements and ethical concepts.   
 
Why products? 
   The word “product” signifies that the component of the human body made suitable for 
clinical use results from a variable process involving human labour and technological 
intervention. The process starts with donor recruitment and selection, includes screening tests 
and possibly interventions to facilitate procurement of the biological materials required, and 
extends through procurement to testing, refinement, repair, or manufacturing of products to 
enhance their quality and safety, as well as their suitability for implantation or use, and to 
preserve them for storage or transportation. Processing includes various forms of labelling, 
packaging and further testing where required, before allocation of an MPHO to a patient 
directly or through a clinical practitioner or a health care institution.  
   Arguably, the term "product" risks alienating these medical resources from their origins in 
human donors, and fails to captures the common understanding of such things as transplanted 
organs or donor gametes. However, "product" aptly describes the reality of even these 
recognizably "human" therapeutic materials, as well as the hundreds of human "biologics" 
that are routinely used and recognised as products by regulators and clinicians. Importantly, 
use of the term "product" serves to reinforce the need for quality systems and for regulatory 
oversight. It emphasises the responsibilities of "producers", clinical users and the national 
authorities in the domain of product liability. The transmission of infectious agents is a 
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concern common to MPHO since the beginning of their widespread application in the early 
20th century. Several public health crises involving MPHO have occurred, such as the 
transmission of HIV through blood products and Creutzfeldt Jacob disease through dura 
mater grafts (Eastlund 1995).  
   MPHO are by no means mere manufactured "medical products":  they are explicitly of 
human origin, which places concern for the human sources from whose bodies they are 
derived at the forefront of discussions concerning them. The human origin of MPHO is easily 
overlooked as products are alienated from donors through time, distance, and attenuation of 
recognizably human features, yet it provides a rationale and common ground for a united 
approach to governance of all MPHO, regardless of the many differences between them. 
The challenges of failed governance 
 Insufficient or untimely access to suitably matched MPHO remains a major challenge within 
most healthcare systems. For some countries, provision of MPHO such as gametes for use in 
ART or even organs for transplantation may be a low priority in the face of competing 
healthcare needs. Nevertheless, shortages are a critical concern for many countries at varying 
levels of development. The shortage in organs for transplantation is perhaps the best 
publicised example, yet access to safe blood transfusion still represents a major public health 
concern (WHO 2012). Despite estimates of more than 150,000 corneal grafts performed 
worldwide each year, unmet demand is a major problem in countries from India to Canada 
(Oliva et al. 2011; Lakey et al. 2007). Little is known about gamete shortages; prospective 
recipients may wait for two years for sperm in China (Ping et al. 2011), or up to 6 years for 
ova in France (Martin and Kane 2014). Demand for human tissue products is also largely 
unquantified, but sufficiency of supplies remains a concern even in North America where 
hundreds of thousands of grafts are performed each year (Lakey et al. 2007; Shiroff et al. 
2014). 
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    Where demand for MPHO exceeds the available supply, this may create opportunities for 
exploitation of vulnerable prospective source individuals and recipients, especially through 
commercial activities. The wellbeing and autonomy of donors and recipients may be 
compromised where provision of care conflicts with profit making, and equity in access to 
MPHO and in donation of materials for MPHO production will be undermined where 
financial incentives influence donor recruitment or MPHO allocation. 
    There are many varieties of trafficking in human body parts, some of which involve 
trafficking in human beings for removal of organs, ova or other biological materials used in 
MPHO. Trafficking activities also include illicit diversion of legitimately acquired MPHO, or 
various illicit activities in procurement, trade or use of MPHO without trafficking in human 
beings as such (López-Fraga et al. 2014). Among the diverse reports of illicit activities in 
MPHO procurement and use, violations of laws and regulations are often revealed seemingly 
by chance, following the deaths of donors or recipients (e.g. Sachan 2014; Reddy et al. 2013; 
Martin 2011, 238), or when scandals are uncovered by investigative journalists, researchers 
or health professionals (e.g. Scheper-Hughes 2007; Jing 2006). Predators take advantage of 
individuals and communities at moments of vulnerability due to economic crisis, natural 
disasters, civil unrest or war, to source materials that may be sold for profit. Recipients of 
such MPHO may be unaware or disinclined to question the origin of these precious resources. 
The human source is easily obscured where linguistic, cultural, geographical and political 
barriers may impair efforts to trace and identify donors. The increasing use of the internet in 
MPHO trade and trafficking, and the falsification of documents at the point of procurement, 
throughout processing and in the labelling of MPHO further undermines transparency.  
   A common biology and physiology enables a transnational movement of MPHO between 
human beings transcending culture, race, gender, age, religion, and citizenship. In an 
increasingly globalized world, exchange or sharing of MPHO may exemplify the reality of a 
single common humanity. In this setting, "survival cannibalism" may be both justifiable and 
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admirable. Yet in the absence of effective laws and regulations to protect communities and 
individuals, procurement and use of MPHO reveals the darker side of such cannibalism: a 
consumption that may destroy and efface the donor.  
Governance of MPHO: a responsibility for national authorities 
   Although inadequate donation rates - especially of organs - attract significant public 
attention, the problem of MPHO shortages is multifactorial. In addition to donor recruitment 
issues, health systems require organizational infrastructure for procurement, processing, 
allocation and clinical application of MPHO. Society, through its governing authorities, has 
responsibility for the organization and oversight of MPHO services. Measures must be 
adopted within jurisdictions to enable service delivery during routine and crisis periods.     
Societal concern for health equity, as well as justice in the distribution of scarce resources 
contributed by the public, should guide efforts by policy makers to promote equity in access 
to MPHO. Objective clinical criteria and ethical norms should inform the allocation of 
MPHO, uninfluenced by the economic status of potential recipients or opportunities for 
financial gain among service providers. Further, authorities must regulate - and where 
necessary prohibit - practices that could result in harm to donors, recipients, and the public. 
Legislation is essential but requires an effective implementation and enforcement for 
protection of donors and recipients. Necessary protective measures include adoption of best 
practice standards of care, safety and quality from donor selection and follow-up to assessing 
long-term outcomes in the recipient.  
   National authorities should also recognize governance responsibilities that may arise in the 
setting of transnational activities. Where domestic policies and practices, or the actions of 
citizens abroad endanger foreign citizens and communities, authorities should strive to 
address these issues within the domestic jurisdiction and through international collaboration. 
A variety of international instruments provide tools with which to address particular areas of 
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concern in the transnational setting, notably the Convention against Organ Trafficking soon 
to be adopted by the Council of Europe (López-Fraga et al. 2014), and the (2004) United 
Nations Protocol to Prevent, Suppress and Punish Trafficking in Persons which explicitly 
addresses human trafficking for the purpose of organ removal. There is, however, no 
comprehensive legally binding instrument to mandate minimum standards of practice with 
regards to MPHO, nor to address the issues of commercialism and trafficking that may arise 
for any MPHO. International scientific and professional societies such as the Transplantation 
Society and the International Society of Nephrology, which together led the development of 
the Declaration of Istanbul on Organ Trafficking and Transplant Tourism, have 
demonstrated the impact of transnational collaborative action in fostering leadership, capacity 
building, harmonizing global standards, and combatting unethical practices (Danovitch and 
Al-Mousawi 2012).  
The self-sufficiency paradigm  
The important role of governing authorities in meeting societal needs for MPHO must be 
complemented by societal recognition of responsibility for donation of biological materials 
where possible. Where equitable allocation programs for specific MPHO are established, all 
are potential recipients of MPHO and thus may rightly be considered potential donors: a 
reciprocal duty to contribute to efforts in meeting needs arises from the expectation of having 
one's own needs met. This ethos of shared responsibility and solidarity in meeting needs 
within a community underpins the self-sufficiency paradigm, which has now been invoked as 
a goal for policy makers and a foundation for governance of MPHO in the context of blood 
(WHO 2012), organs (Delmonico et al. 2011) and gametes (Martin and Kane 2014). 
   Self-sufficiency in a particular MPHO consists in meeting the needs of patients from a 
given population with an adequate provision of transplantation services and supply of that 
MPHO derived from the population. Key strategies identified for the successful pursuit of 
 7 
self-sufficiency were identified in the context of organs for transplantation during the Third 
WHO Global Consultation on Organ Donation and Transplantation (WHO 2011), which may 
be applied to all MPHO: 
• government support and oversight, enabling the contribution of all members of 
society; 
• equity in donation among possible donors and equity in allocation; 
• donation education and health promotion with prevention of needs and integration 
with public health programs; 
• trust of all stakeholders including the public, through transparency and 
professionalism.  
 
Equity, reciprocity, and solidarity are principles inherent to the self-sufficiency paradigm, in 
the context of a shared commitment to assist in meeting therapeutic needs while avoiding 
harm to donors, recipients and the community. These principles are applicable to all MPHO 
despite their important differences. Challenges in motivating donation, assuring equity of 
access, and protecting donors and recipients are common to all MPHO by virtue of their 
shared human origins and destinations, although the degree of difficulty in addressing these 
challenges will vary according to the MPHO concerned and the societal context in which 
self-sufficiency in pursued (Martin 2010, 388). A population adopting the goal of self-
sufficiency in particular MPHO may be defined by jurisdictional limits or organizational 
boundaries that are essential to effective procurement and distribution of MPHO. 
Transnational agreements may allow small countries to pool their resources and work 
together to meet needs more efficiently. Furthermore, for some MPHO meeting needs 
effectively requires global engagement to assist in matching prospective donors and 
recipients across the world (ibid. 387).  
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Rejection of financial gain in the human body 
   The use of financial incentives to recruit providers of biological materials for use in MPHO 
is excluded by the self-sufficiency paradigm, as these will exacerbate inequities in the 
distribution of donors. Conversely, the removal of financial barriers to participation in 
donation opportunities, for example through coverage of expenses incurred by donors, is 
recommended as a strategy to promote equity and facilitate donation. Financial incentives 
would also impair efforts to promote donation as a reciprocal duty to be embraced by all 
those who enjoy the privilege of access to MPHO. Furthermore, there are well founded 
concerns that trade in MPHO - whether regulated or illicit - exacerbates risks of harm to 
potential donors and recipients including coercion, exploitation, commodification, and 
compromised safety (e.g. Epstein et al. 2011; Pfeffer 2011; Pirnay et al. 2012). These harms 
derive from conflicts of interest that arise where donors, donor families, recipients, health 
professionals and others involved in procurement, use and distribution of MPHO may derive 
profits that exceed the recovery of standard costs incurred during these processes.  
   Claims that financial incentives are necessary to assure sufficient supplies of MPHO are not 
supported by the evidence of progress towards self-sufficiency where prohibition of trade has 
been complemented by strategic efforts to remove barriers to donation, to encourage 
donation, and to prevent needs for MPHO where possible. For example, Norway is 
effectively self-sufficient in renal transplantation, with an annual transplantation rate of 60 
per million population matching the annual incidence of patients added to the - notably 
transparent and equitable -waiting list for transplantation (Figure 1) (Reisaeter et al. 2011). 
The key difference between Norway and the United States - where the gap between supply 
and demand shows little evidence of shrinking - appears to be the three fold difference in the 
incidence of end stage renal disease in the USA. Incentive proposals frame the organ shortage 
as a simple problem of "supply and demand" that is best resolved by increasing supplies, and 
fail to consider that public health interventions may significantly reduce demand. 
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The WHO MPHO initiative 
All MPHO present risks for safety that mandate traceability, vigilance and surveillance; all 
present potential ethical hazards in donor recruitment and procurement of materials that 
mandate legislation, transparent consent policies and standards of care to assure respect for 
the human rights of potential donors. These commonalities provide grounds for a shared 
framework for governance of all MPHO. 
    The WHO has developed an initiative on MPHO that builds on the self-sufficiency 
paradigm to explore novel strategies and to encourage unprecedented efforts to meet needs, 
while protecting the human body and its parts as such from becoming the source of financial 
gain. The initiative is currently undergoing discussion and refinement through consultation 
with experts, scientific and professional societies and representatives of Member States from 
all regions. It proposes to foster globally harmonized standards of practice for MPHO and 
common tools to guide and support services providing MPHO from donation through to 
clinical application. Its objective is to address the ethical concerns inherent to the human 
origin of these medical products while effectively and efficiently meeting patient needs. To 
achieve this goal, development and implementation of three complementary international 
resources to harmonize and improve access, safety, quality and ethics of MPHO services is 
proposed. First, a set of standards for practice addressing issues inherent to the human origin 
of these medical products; second, the universal use of a consistent coding system for MPHO, 
the Information Standards for Blood and Transplant “ISBT 128” (Warwick et al. 2013); third, 
a set of tools that exploits the global experience of vigilance and surveillance (V&S) for 
MPHO for the benefit of all donors and recipients. 
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Standards of Practice  
The Standards of Practice Inherent to MPHO derive from various sources including the WHO 
Guiding Principles on human cell, tissue and organ transplantation (WHO 2010), and are 
currently undergoing development and revision. The aim of these crosscutting standards is to 
encompass the implications of the human origin of these medical products for their 
procurement, distribution and use. The Standards recognize features of the self-sufficiency 
paradigm such as the responsibility of authorities and through them, of each of member of 
society, for meeting MPHO needs. Likewise, the Standards highlight the importance of 
equity in donation and in the allocation of MPHO. The Standards require free, informed and 
specific consent of living donors and recipients of MPHO, protection of those incompetent to 
consent, and a legislative framework to support donation after death. Further, they emphasise 
the provision of education for children about donation and prevention of needs of MPHO, as 
a core component of public health policy, empowering citizens to participate in future 
donation opportunities.  
   In prohibiting financial gain on the human body and its parts as such, the Standards affirm 
the non-commercial nature of MPHO. Noting that such financial gain is not prohibited in 
some countries, they emphasise the role of transparency in practice and policy. While 
protecting the privacy and confidentiality of donors and recipients is critical, transparency 
establishes and maintains public trust, and facilitates traceability, evaluation of outcomes, 
vigilance and surveillance such that quality, safety and efficiency of MPHO use may be 
optimised.  
Universal coding with “ISBT 128” 
ISBT 128 is a global coding system for MPHO used in 75 countries, in all regions of the 
WHO, by more than 4,600 establishments responsible for MPHO management. The 
International Council for Commonality in Blood Banking Automation (ICCBBA), a non-
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governmental organization in official relations with WHO, manages ISBT 128 to ensure a 
unique identifier is available for each MPHO and for each MPHO establishment in order to 
provide traceability for each product. ICCBBA maintains a globally consensual terminology 
of thousands of well-described MPHO that can be translated in any language and coded with 
ISBT 128 to create identifying labels of universal readability.  
   Harmonization of coding in this way enables information about products and their 
characteristics and qualifiers to be transferred without risk of human error thanks to 
established formats and tables. The use of ISBT 128 strengthens safety and traceability and 
transparency concerning the origin and nature of MPHO within a country and internationally. 
A common, consistent language and identification system facilitates data collection and 
analysis, including rapid tracing of recipients at risk, or sourcing of urgently needed MPHO.  
Optimizing global vigilance and surveillance 
The NOTIFY project associates WHO and the Italian National Transplant Centre (CNT), a 
WHO collaborating centre on V&S for human cells, tissues and organs (Fehily et al. 2013). 
Under the oversight of health authorities and in close collaboration with professionals, V&S 
enables recognition and management of risks, many of which are common to all types of 
MPHO. A risk recognized for the first time with one type of MPHO may be anticipated with 
others, thus by sharing V&S data, the global community has the opportunity to learn from 
experiences of adverse events elsewhere in the world, or in different clinical contexts. 
NOTIFY maintains tools to promote development of national V&S systems and to optimize 
the use of V&S data by the global community through engagement with scientific and 
professional societies. For instance, the NOTIFY website (www.notifylibrary.org) hosts the 
NOTIFY library, a public database currently containing more than 1800 references 
corresponding to 949 case reports of adverse occurrences wherein a risk was identified or 
harm incurred.  
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Conclusion 
The WHO initiative aims to promote recognition and respect for MPHO as exceptional 
therapeutic resources through the universal adoption of a globally transparent coding system 
ISBT128, the mutualisation of V&S information and tools, and the harmonisation of 
standards of practice as applied to all MPHO. The initiative also aims to foster global 
consensus on the non-commercial nature of the human body and its parts as such, and to 
develop the ethical framework of the self-sufficiency paradigm to assist societies as they 
strive to meet their needs for these resources responsibly. Insufficient supplies of MPHO 
result in premature deaths, missed opportunities to restore health and additional costs for 
healthcare systems. Common origins in the human person distinguish these from all other 
medical products, and provide grounds for a common approach to governance and strategy in 
their procurement, distribution and use. 
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Figure 1: Waiting list additions versus kidney transplants performed in 2011 per million 
population: High-income countries 
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